NASDAQ:SPRO

Spero Therapeutics Stock Forecast, Price & News

$14.18
+0.51 (+3.73 %)
(As of 08/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.51
$14.33
50-Day Range
$13.34
$16.39
52-Week Range
$8.50
$23.64
Volume110,231 shs
Average Volume206,411 shs
Market Capitalization$421.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
30 days | 90 days | 365 days | Advanced Chart
Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Spero Therapeutics logo

About Spero Therapeutics

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

608th out of 1,311 stocks

Pharmaceutical Preparations Industry

307th out of 647 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

Is Spero Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spero Therapeutics stock.
View analyst ratings for Spero Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Spero Therapeutics?

Wall Street analysts have given Spero Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Spero Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 2,400,000 shares, a drop of 23.1% from the June 15th total of 3,120,000 shares. Based on an average daily trading volume, of 165,200 shares, the short-interest ratio is presently 14.5 days. Approximately 9.9% of the company's stock are sold short.
View Spero Therapeutics' Short Interest
.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Spero Therapeutics
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings data on Thursday, May, 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.05. The business earned $7.30 million during the quarter, compared to analysts' expectations of $2.71 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 65.11% and a negative net margin of 498.66%.
View Spero Therapeutics' earnings history
.

How has Spero Therapeutics' stock price been impacted by COVID-19?

Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SPRO stock has increased by 83.0% and is now trading at $14.18.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SPRO?

5 brokers have issued 1 year price objectives for Spero Therapeutics' stock. Their forecasts range from $19.00 to $47.00. On average, they anticipate Spero Therapeutics' stock price to reach $32.75 in the next twelve months. This suggests a possible upside of 131.0% from the stock's current price.
View analysts' price targets for Spero Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the following people:
  • Dr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 40, Pay $966.83k)
  • Ms. Cristina Larkin, Chief Operating Officer (Age 51, Pay $639.36k)
  • Dr. David A. Melnick M.D., Chief Medical Officer (Age 69, Pay $647.31k)
  • Mr. Satyavrat Shukla C.F.A., Chief Financial Officer (Age 48)
  • Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 67)
  • Ms. Tamara Lynn Joseph L.L.M., J.D., Chief Legal Officer (Age 58)
  • Mr. Jay Blackington, VP of People Strategy & Culture
  • Mr. Timothy Keutzer, Chief Devel. Officer (Age 53)
  • Dr. Ian A. Critchley, Head of Clinical Microbiology
  • Dr. Susannah Walpole Ph.D., Head of Clinical Operations

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Spero Therapeutics' key competitors?

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.17%), IndexIQ Advisors LLC (0.09%), Russell Investments Group Ltd. (0.06%), Alliancebernstein L.P. (0.05%), Advisor Group Holdings Inc. (0.03%) and Bedel Financial Consulting Inc. (0.01%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics
.

Which institutional investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Russell Investments Group Ltd., New York State Common Retirement Fund, and IndexIQ Advisors LLC. Company insiders that have sold Spero Therapeutics company stock in the last year include Ankit Mahadevia, Aquilo Capital Management, Llc, and Cristina Larkin.
View insider buying and selling activity for Spero Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Spero Therapeutics stock?

SPRO stock was bought by a variety of institutional investors in the last quarter, including Bedel Financial Consulting Inc., and Alliancebernstein L.P..
View insider buying and selling activity for Spero Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $14.18.

How much money does Spero Therapeutics make?

Spero Therapeutics has a market capitalization of $421.13 million and generates $9.33 million in revenue each year. The company earns $-78,280,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

How many employees does Spero Therapeutics have?

Spero Therapeutics employs 89 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

Where are Spero Therapeutics' headquarters?

Spero Therapeutics is headquartered at 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]


This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.